The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib

Summary

It has been widely accepted that microparticles expose phosphatidylserine which in turn binds annexin V. It was the objective of this study to compare the antigenic characteristics and phospholipid-dependent procoagulant activity of annexin V positive and -negative subpopulations of platelet-derived microparticles. Annexin V positive and -negative microparticles were identified and characterised using flow cytometry and procoagulant activity was measured by a phospholipid-dependent assay (XACT). In unstimulated platelet-poor plasma, 80% of platelet-derived microparticles failed to bind annexin V. Varying the assay constituents (buffer, calcium and annexin V concentration) did not alter annexin V binding. The proportion of microparticles that bound annexin V was dependent upon the agonist, with physiological agonists such as collagen resulting in fewer annexin V binding microparticles than non-physiological agonists such as ionophore. CD42b (glycoprotein Ib) expression was significantly decreased and CD62p and CD63 expression were significantly increased in annexin V positive compared to annexin V negative subpopulations. There was no significant difference in CD41, CD61, CD42a and CD40L expression between annexin V positive and -negative subpopulations. A significant correlation between annexin V binding and XACT was found (p=0.033). Annexin V inhibited greater than 95% of phospholipid activity, suggesting that annexin V binding was a true reflection of procoagulant activity. The majority of platelet-derived microparticles in unstimulated plasma failed to bind annexin V and showed significantly increased levels of CD42b compared to annexin V positive events. Phospholipid-dependent procoagulant activity is limited to the annexin V positive subpopulation and is agonist-dependent. The significance of annexin V negative microparticles is unclear, however, it is possible that they possess other activities aside from procoagulant phospholipid activity.

Keywords

Annexin V - flow cytometry - microparticles - phosphatidylserine - XACT

• References

• 1 Sinauridze EI, Kireev DA, Popenko NY. et al. Platelet microparticle membranes have 50– to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-434.
• 2 Bode AP, Sandberg H, Dombrose FA. et al. Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation. Thromb Res 1985; 39: 49-61.
• 3 Huisse MG, Ajzenberg N, Feldman L. et al. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost 2009; 101: 734-740.
• 4 Haubold K, Rink M, Spath B. et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009; 101: 1147-1155.
• 5 Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420-17423.
• 6 Ahn YS, Jy W, Jimenez JJ. et al. More on: cellular microparticles: what are they bad or good for?. J Thromb Haemost 2004; 02: 1215-1216.
• 7 Boulanger CM, Amabile N, Tedgui A. Circulating Microparticles. A Potential Prognostic Marker for Atherosclerotic Vascular Disease. Hypertension 2006; 48: 1-7.
• 8 Dignat-George F, Sabatier F, Camoin-Jau L. et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 02: 1844-1845.
• 9 Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Sem Thromb Haemost 2007; 33: 771-779.
• 10 Jimenez JJ, Jy W, Mauro LM. et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109: 175-180.
• 11 Exner T, Joseph J, Low J. et al. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid. Blood Coagul Fibrinolysis 2003; 14: 773-779.
• 12 Connor DE, Exner T, Ma DD. et al. Detection of the procoagulant activity of microparticle-associated phosphatidylserine using XACT. Blood Coagul Fibrinolysis 2009; 20: 558-564.
• 13 Parsi K, Exner T, Connor DE. et al. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg 2007; 34: 731-740.
• 14 Exner T, Joseph J, Low J. et al. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid. Blood Coagul Fibrinolysis 2003; 14: 773-779.
• 15 Biro E, Nieuwland R, Sturk A. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004; 02: 1843-1844.
• 16 Sandberg H, Bode AP, Dombrose FA. et al. Expression of coagulant activity in human platelets: release of membranous vesicles providing platelet factor 1 and platelet factor 3. Thromb Res 1985; 39: 63-79.
• 17 Hemker HC, van Rijn JL, Rosing J. et al. Platelet membrane involvement in blood coagulation. Blood Cells 1983; 09: 303-317.
• 18 Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66-74.
• 19 Dachary-Prigent J, Freyssinet JM, Pasquet JM. et al. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood 1993; 81: 2554-2565.
• 20 Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC. et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96: 3534-3541.
• 21 Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem 1991; 266: 24302-24307.
• 22 Perez-Pujol S, Marker PH, Key NS. Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry 2007; 71: 38-45.
• 23 Becker CK, Parker JW, Hechinger MT. Is forward scatter monotonic on commercial flow cytometers? ISAC, XXI COngress, San Diego, CA. Cytometry 2002; 47 (Suppl. 11) Abstract.
• 24 Shapiro HM. Parameters and Probes. In: Shapiro HM. editor. Practical Flow Cytometry. Fourth Edition ed. John Wiley and Sons Inc.; New York: 2003. pp. 273-410.
• 25 Chow TW, Hellums JD, Thiagarajan P. Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation. J Lab Clin Med 2000; 135: 66-72.
• 26 Jy W, Horstman LL, Arce M. et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119: 334-345.
• 27 Comfurius P, Senden JM, Tilly RH. et al. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta 1990; 1026: 153-160.
• 28 Andree HA, Stuart MC, Hermens WT. et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-17912.
• 29 Zdebska E, Wozniak J, Dzieciatkowska A. et al. In comparison to progenitor platelets, microparticles are deficient in GpIb, GpIb-derived carbohydrates, glycerophospholipids, glycosphingolipids, and ceramides. Acta Biochim Pol 1998; 45: 417-428.
• 30 Heijnen HF, Schiel AE, Fijnheer R. et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94: 3791-3799.